Pancreatic Cancer Research

ResearcherHonorHealthActive in the last 2 years

Muhammad Rizwan Khawaja

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7436-0891; OpenAlex author ID A5065201152. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.36401/jipo-25-20↗
  2. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience. Co-author DOI 10.1097/coc.0000000000000115↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Derek Cridebring · 1 shared paper, 2026 · strength 0.25
  2. Gayle Jameson · 1 shared paper, 2026 · strength 0.25
  3. Haiyong Han · 1 shared paper, 2026 · strength 0.25
  4. Erkut Hasan Borazanci · 1 shared paper, 2026 · strength 0.25
  5. Daniel D. Von Hoff · 1 shared paper, 2026 · strength 0.25
  6. Boris Ν. Kholodenko · 1 shared paper, 2026 · strength 0.25
  7. Higinia Rosa Cardenes · 1 shared paper, 2017 · strength 0.07
  8. Patrick Joseph Loehrer · 1 shared paper, 2017 · strength 0.07
  9. Elena Gabriela Chiorean · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.